SG&A Efficiency Analysis: Comparing Amgen Inc. and Amneal Pharmaceuticals, Inc.

SG&A Efficiency: A Tale of Two Pharmaceutical Giants

In the competitive landscape of pharmaceuticals, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Amgen Inc. and Amneal Pharmaceuticals, Inc. have showcased contrasting strategies in managing these costs. From 2014 to 2023, Amgen's SG&A expenses have consistently grown, peaking at approximately $6.2 billion in 2023, reflecting a 31% increase from 2014. This growth underscores Amgen's expansive operational strategies and robust market presence. In contrast, Amneal Pharmaceuticals, Inc. has maintained a more conservative approach, with SG&A expenses rising from $84.6 million in 2014 to $429.7 million in 2023, marking a significant 408% increase. This sharp rise indicates Amneal's aggressive expansion and investment in market penetration. These trends highlight the diverse approaches in managing operational costs, offering insights into each company's strategic priorities.